Allergan buys QLT’s acne drug
Under the terms of the agreement, QLT will receive a one-time cash payment of approximately $150 million upon closing, which is expected to occur in the third quarter
The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics licence application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) to treat adults with primary membranous nephropathy (pMN).
Radius selected RAD140 from a series of promising selective androgen receptor modulators (SARM) after it demonstrated exceptional selectivity for anabolic activity in well-validated in vivo models. Radius expects